Kartos Therapeutics is a clinical stage biopharmaceutical company based in Redwood City, CA, dedicated to the development of novel, targeted therapeutics that significantly enhance the lives of cancer patients. Their focus lies in the MDM2-p53 interaction, a promising therapeutic target with the potential to offer new treatment options for selected solid tumors and hematological malignancies.
With their investigational MDM2 inhibitor, navtemadlin KRT-232, Kartos Therapeutics aims to provide a potent and selective oral medication that can effectively inhibit MDM2, offering hope for improved outcomes in cancer treatment.
Generated from the website